Users report benefits with Regaine data shows Regaine effective for hair regrowth and stopping further hair loss in men and women

New Orleans, USA (25 February 2002) -

In a review of minoxidil clinical data presented at the 60th American Academy of Dermatology Annual Meeting, Regaine® 5% (minoxidil topical solution) was associated with either no change or hair regrowth from baseline in up to 94% of male users.

Consumer research indicates that prevention of further hair loss may be as important as regrowth of hair.

The data presented in this poster show that overall, minoxidil topical solution (MTS) is effective in both re-growing hair and preventing further hair loss. In the evaluation to assess the efficacy of Regaine in preventing further hair loss, data were evaluated from four sources in the Regaine clinical database: a prospective post-marketing surveillance study; a retrospective analysis of four pivotal, double-blind, randomised, placebo-controlled trials; five-year follow-up data from a long term clinical study; and global panel photographic evaluations.

The overall results showed that 4 out of 5 adults using Regaine 5% showed hair regrowth or no further loss of hair.

"Regaine offers patients a safe and effective treatment that may prevent further hair loss as well as regrow hair in both men and women," said Dr Tony Chu, Consultant Dermatologist, Hammersmith Hospital, UK. "Once hair loss begins, it continues in a steady progression so it is important to start treatments at the first signs of hair loss."

In a retrospective review of four double blind randomised trials of MTS 5% and 2% (n=1,054) showed that hair regrowth or no further hair loss occurred in 75% to 96% of men (compared to 56% to 67% with placebo) and 85% to 89% of women (compared to 69% to 73% with placebo).

Likewise, five-year follow-up data from a subgroup of men (n=31) confirmed that regrowth or no further hair loss was maintained in 91% of men at 1 year and 81% of men after 4.5 to 5 years.

In addition, a large post-marketing surveillance study, men and women (n=11,122) were asked to prospectively rate treatment efficacy of minoxidil 2% in demonstrating the slowing or stopping of hair loss.

Ninety-two percent of the subjects rated Regaine excellent, good or fair in slowing or stopping hair loss after one year of use.

These patient reports were further supported by the global panel photographic evaluations where 83% to 94% of men were rated as achieving clinical response in slowing or stopping hair loss with Regaine 5% after 48 weeks.

Regaine is the first topical product proven to treat hereditary hair loss in men and women. Regaine has been approved in many countries around the world including the USA (where it is known as Rogaine), Europe, Latin America and Japan.

Pharmacia (NYSE: PHA) is a top-tier global pharmaceutical company with a leading agricultural subsidiary. Pharmacia's innovative medicines and other products save lives and enhance health and wellness.

Pharmacia's 59,000 people work together with many diverse stakeholders to bring these benefits to people around the world, and to create new health solutions for the future.